Diffuse large B-cell lymphoma
Conditions
Interventions
Experimental group:Receive Fuzheng Jiedu prescription combined with standard treatment.
Control group:Receive only standard treatment.
Sponsors
Shanghai tenth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria Age: Adult patients 18 years and older. Diagnosis: Diffuse large B-cell lymphoma (DLBCL) was confirmed which met the WHO classification criteria. Stage: Any clinical stage (stage I-IV) that may include patients with initial treatment or relapse. Treatment history: May include patients who have not received treatment or patients who have received monotherapy. Physiological state: have good physiological state Karnofsky score =70. Informed consent: Be able to understand the purpose of the study and sign informed consent.
Exclusion criteria
Exclusion criteria: Exclusion criteria Complicated diseases: There are serious cardiovascular liver kidney and other organ insufficiency or other major diseases. Other tumors: Patients who have had other malignancies recently (within the last 5 years). Allergy history: Patients with a history of allergy to the ingredients of the investigational drug. Immunosuppression: Patients who are receiving immunosuppressive treatment (such as long-term use of hormones or chemotherapy). Pregnancy or lactation: Female patients were pregnant nursing or planning to become pregnant during the study period. Participating in other studies: Patients currently participating in other clinical studies.(YNMT)·
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of CD8+ T cell subsets;overall survival;The proportion of CD4+T cell subsets;progression free survival; | — |
Countries
China
Contacts
Public ContactYidong Zhu
Shanghai tenth People's Hospital
Outcome results
None listed